Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study

Erna C. van Balen MSc, MPhil | Shermarke Hassan MSc | Cees Smit | Mariette H. E. Driessens PhD | Erik A. M. Beckers MD, PhD | Michiel Coppens MD, PhD | Jeroen C. Elkenboom MD, PhD | Hélène L. Hooimeijer MD | Frank W. G. Leebeek MD, PhD | Evelien P. Mauser-Bunschoten MD, PhD | Lize F. D. van Vulpen MD, PhD | Saskia E. M. Schols MD, PhD | Frits R. Rosendaal MD, PhD | Samantha Gouw MD, PhD

1Department of Clinical Epidemiology, Leiden University Medical Center, The Netherlands
2Netherlands Hemophilia Society (NVHP), Nijkerk, The Netherlands
3Department of Hematology, Maastricht University Medical Centre, Maastricht, The Netherlands
4Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
5Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
6Department of Paediatrics, University Medical Center Groningen, Groningen, The Netherlands
7Department of Hematology, Erasmus University Medical Center, Erasmus MC, Rotterdam, The Netherlands
8Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands
9Department of Hematology, Radboud university medical center, Nijmegen, The Netherlands
10Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Nijmegen, The Netherlands
11Center for Clinical Transfusion Research, Sanquin Research/LUMC, Leiden, The Netherlands
12Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

Correspondence
Samantha Gouw, Department of Clinical Epidemiology, Postzone C7-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Email: s.c.gouw@amsterdamumc.nl

Funding information
This study was funded by the Dutch Ministry of Health, Welfare and Sports as part of the Hemophilia in the Netherlands study and by the Dutch Hemophilia Foundation (Stichting Hemofilia).

Handling Editor: Pantep Angchaisuksiri

Abstract

Background and objectives: Treatment availability and comprehensive care have resulted in improved clinical outcomes for persons with hemophilia. Recent data on socioeconomic participation in the Netherlands are lacking. This study assessed participation in education, in the labor market, and social participation for persons with hemophilia compared with the general male population.

Methods: Dutch adults and children (5–75 years) of all hemophilia severities (n = 1009) participated in a questionnaire study that included sociodemographic, occupational, and educational variables. Clinical characteristics were extracted from electronic medical records. General population data were extracted from Statistics Netherlands. Social participation was assessed with the PROMIS Ability to Participate in Social Roles and Activities short form, with a minimal important difference set at 1.0.
Essentials

- Current socio-economic participation of Dutch persons with hemophilia is unknown.
- Participation in education and in the labor market, and social participation were assessed.
- Educational outcomes were similar to or better than in the general population.
- Labor market outcomes were similar to the general population for non-severe hemophilia.

1 | INTRODUCTION

The X-linked congenital bleeding disorder hemophilia is characterized by an increased bleeding tendency because of a deficiency of functional coagulation factor VIII (hemophilia A) or IX (hemophilia B). It is classified into severe (<0.01 IU/ml FVIII or FIX), moderate (0.01–0.05 IU/ml FVIII or FIX) or mild (0.05–0.40 IU/ml FVIII or FIX) hemophilia. Bleeding occurs spontaneously in joints and muscles in persons with severe hemophilia, or when triggered by major trauma or surgery in persons with mild or moderate hemophilia. In the long term, recurrent bleeding causes irreversible joint damage, which may lead to disability.

Treatment first became available in high-income countries in the late 1960s. Modern treatment mostly consists of intravenous infusion of factor VIII or IX replacement products: 2–3 times a week as prophylaxis for severe hemophilia, or as treatment of bleeds in mild and moderate hemophilia (“on-demand”). The majority of persons with severe hemophilia have received prophylaxis since the mid-1980s. A potential side effect of these products is the development of neutralizing antibodies (“inhibitors”). Also, bloodborne pathogens were transmitted through plasma-derived treatment products, such as HIV between 1980–1985 and hepatitis C until the early 1990s. Nonfactor replacement hemostatic agents have been marketed in the past few years as alternative prophylactic treatment.

Hemophilia care in the Netherlands is organized in six comprehensive hemophilia treatment centers distributed over nine locations across the country according to the European principles of Hemophilia Care. Bleeding rates, joint impairment, consequences of comorbidities, life expectancy, and several aspects of health-related quality of life have improved tremendously in the Netherlands since the 1970s. No recent data are available for socioeconomic participation in the Netherlands, even though the ability to participate in daily life is among the most important health outcomes for persons with hemophilia. Insight into socioeconomic participation will help to evaluate the effects of comprehensive care over time.

Several recent studies from other high-income countries suggested negative impacts of hemophilia on employment and disability rates, absenteeism from work or school, perceived impact on education or career, and social functioning. Dutch young adults with nonsevere hemophilia were more likely to have paid employment than those with severe hemophilia. Among persons with severe hemophilia A in five European countries, lifelong prophylaxis and high therapy adherence led to reduced activity impairment and work productivity loss, whereas frequent bleeds and pain were associated with increased activity impairment and work productivity loss.

Few studies have examined the “gap” in socioeconomic participation between persons with different severities of hemophilia and the general population. Furthermore, participation outcomes are often not reported in a standardized manner (i.e.,
using internationally recognized indicators that allow for comparison across settings. For example, the most important indicators labor market participation are the unemployment rate and the employment-to-population ratio. Absenteeism from work and occupational disability are indicators of temporary and (semi-)permanent limitations on the labor market, and as such reflect the health status of a population.

The aim of the current study was to assess participation of the Dutch hemophilia population, focused on participation in education and the labor market, and social participation, and to compare these outcomes with the general male population using standardized indicators.

## METHODS

### Study design

The Hemophilia in the Netherlands (HiN) studies are a series of cross-sectional studies that provide a comprehensive evaluation of the medical, psychosocial, and socioeconomic situation of the Dutch hemophilia population since 1972. The sixth edition, HiN-6, was conducted during 2018–2019. Approval was obtained from the Medical Ethics Committee at Leiden University Medical Center, the Netherlands.

### Participants and procedures

All Dutch male adults and children with mild, moderate, or severe congenital hemophilia A or B (<40 IU/ml coagulation factor VIII/IX) receiving treatment from one of six Dutch hemophilia treatment centers were invited by letter to participate between June 2018 and July 2019. Excluded were females with hemophilia, persons with acquired hemophilia, and nonhemophilic individuals with reduced FVIII levels resulting from von Willebrand disease. Individuals between 5 and 75 years were included in the analyses.

Individuals who agreed to participate received a comprehensive questionnaire (hard copy or electronic; captured with the Castor Electronic Data Capture system). Participants were reminded during their regular outpatient clinic appointment and two reminders were sent by email. Three questionnaire versions were available: children aged 0–11 years (completed by parents), teenagers aged 12–17 years, and adults of 18 years and older. Clinical characteristics were extracted from medical records if the participant (or parents) had signed written informed consent. If the participant did not consent, only self-reported data from the questionnaire were used. Hemophilia severity was known for all responders and nonresponders.

### Data collected

The questionnaire contained clinical and sociodemographic questions: chronic joint problems due to hemophilia (defined as "do you have any chronic joint problems due to hemophilia" [yes/no]), current and highest completed education level, work status, time missed from work or school in the past year, and the perceived impact of hemophilia on education and career (yes/no and an open-ended question). Social participation was assessed with the PROMIS-29 Profile v2.01 Ability to Participate in Social Roles and Activities. In brief, PROMIS short forms are based on Item Response Theory, which provides valid and reliable results that can be compared across populations. The ability to participate is measured with four items, each scored from 1 to 5; a higher score indicates better social participation.

The following clinical characteristics were collected: date of birth, type of hemophilia (A or B), severity of hemophilia based on factor VIII or factor IX activity (severe: <0.01 IU/ml; moderate: 0.01–0.05 IU/ml; or mild: >0.05–0.40 IU/ml), prophylaxis use (yes/no), inhibitor status (current/past/never), HIV infection (yes/no), and hepatitis C virus status (currently/past/never infected).

### Outcomes and definitions

Three types of outcomes were assessed in partially overlapping populations: educational outcomes, labor market participation, and the ability to participate in social roles and activities.

**Educational outcomes** were assessed according to the International Standard Classification of Education (ISCED). The following educational outcomes were assessed: (1) participation in education, defined as the proportions of 15 to 19 and 20 to 24 year olds enrolled in formal education; (2) educational attainment, defined as the percentage of the population aged 15–75 years that completed at least upper secondary education (ISCED level 3), which is the Dutch minimally required qualification considered sufficient to enter the labor market; (3) absenteeism from school because of hemophilia, defined as the number of days missed from school in the past 12 months from hemophilia (bleeds or outpatient clinic visits) for individuals aged 5 years and older enrolled in formal education.

**Labor market participation** was assessed using internationally recognized labor market indicators. The study population for labor market outcomes consisted of individuals aged 15–75 years. Participants were either part of the labor force (individuals with paid employment) or the nonlabor force (full-time students, retirees, individuals with an occupational disability, unemployed).

The following outcomes were reported: (1) the employment-to-population ratio, defined as the proportion with paid employment for at least 1 hour a week (including self-employed persons) relative to the study population; (2) unemployment, defined as the proportion of the labor force without paid employment who were available for the labor market and actively looking for work; (3) occupational disability, defined as the proportion of the study population being unable to obtain or maintain paid employment from an illness or disability (with ≥80% disability considered fully occupationally disabled according to Dutch law) proportion of individuals working full-time (i.e., ≥36 hours a week).
among employed persons; (5) absenteeism from work, defined as the total number of days missed from work, and the number of days missed from work due to hemophilia (bleeds or outpatient clinic visits) in the past 12 months for individuals with paid employment; and (6) perceived impact of hemophilia on education or career.

The ability to participate in social roles and activities was assessed for adults (≥18 years) by calculating T-scores for the PROMIS-29 Ability to Participate in Social Roles and Activities domain using the Health Measures Scoring Service. T-scores are a normalized score with a population mean of 50 and a standard deviation (SD) on 10 in the reference population (the US general population).

2.5 | Data analysis and comparisons

Educational outcomes and labor market indicators were compared with aggregate-level data from the Dutch general male population when possible, as specified in the following section.

Descriptive statistics (N, %, median, interquartile range [IQR]) were mainly used, categorized according to disease severity. Educational outcomes and labor market participation were presented as percentages with 95% confidence intervals (CI) and stratified by hemophilia severity, type, and inhibitor status. If confidence intervals for our estimates did not include the estimate for the general population, we consider our estimate to be different from the general male population. The employment-to-population ratio was also stratified by 10-year age groups. The number of days of absenteeism was reported as medians with the IQR. The ability to participate in social roles and activities was presented as mean and median T-scores with IQR, stratified by hemophilia severity.

Participation in education was compared to Organization for Economic Co-operation and Development aggregate data in 2018 (combined for males and females because data for males are not available). Educational attainment was compared with data at the aggregate level from Statistics Netherlands in 2019. Children aged 5–18 years were assumed to be in compulsory education. The only data available for comparisons of school absenteeism was the proportion of Dutch boys in grades 8 (13–14 years old) and 10 (15–16 years old) who reported at least 1 day of school absenteeism in 2015.

The employment-to-population ratio and occupational disability were compared with aggregate data of the general male population aged 15–75 years in 2018, stratified by age group, extracted from Statistics Netherlands. Absenteeism from work was compared with data from Statistics Netherlands in 2018. The impact of hemophilia on career or education and the Ability to Participate in Social Roles and Activities were assessed for adults in three age groups: those born before the introduction of coagulation factor products (born before 1971), those born before the introduction of pathogen inactivation and removal techniques (1971–1992), and those born after the introduction of such techniques (1993 or later). T-scores were plotted by age group and hemophilia severity. The minimal important difference was 1; a difference of ≥1 was considered clinically relevant.

Analyses were performed in IBM SPSS Statistics for Windows, version 25.0.

3 | RESULTS

3.1 | Study population

In total, 2192 adults and children with hemophilia were invited to participate; 1009 of them completed the questionnaire in part or in full (response 46%). Of these 1009 individuals, 906 were between 5 and 75 years (84 children 5–11 years old, 57 adolescents 12–17 years old, and 765 adults) and included in the current analysis. Medical record data were available for 665 of 906 individuals (73.4%). Of all participants, 86.4% had hemophilia A and 339 participants had severe hemophilia (37.4%). Individuals with severe hemophilia were younger (median age 36 years, IQR 20–54) than individuals with moderate (median age 40 years, IQR 25–57.5) and mild hemophilia (median age 48 years, IQR 27–61, Table 1).

3.2 | Educational outcomes

Educational outcomes are summarized in Table 2. Participation in education was 96% (CI 92–100) for 15–19 year olds and 68.1% (CI 57–79) for 20 to 24 year olds, compared with 92% and 53% in the general population, respectively. One-third (33.8%) of individuals enrolled in education also had full-time or part-time work or was self-employed, and another 3.8% was actively looking for work.

Information on educational attainment was missing for 63 individuals. Of 731 remaining participants, 557 (76.2%; CI 73.1–79.3), had completed at least upper secondary education (ISCED level 3), compared with 72.8% in the general male population. Educational attainment was similar across severities and types of hemophilia (Table 2 and Table S1a and b).

Data for school absenteeism because of hemophilia were available for 154 of 263 persons aged 5–75 years who were enrolled in formal education; part of the absenteeism data were missing because of a routing error in the first electronic version of the questionnaire, which was corrected after 6 months. Overall, 69.5% (CI 63.6–75.3) reported absenteeism from hemophilia in the past 12 months (Table 2), compared with 37.8% of Dutch boys in grades 8 and 10. The number of days of absenteeism from hemophilia was higher among individuals with severe hemophilia (median 2 days, IQR 0.9–4.8) than among those with moderate (median 1 day, IQR 0.2–3) and mild hemophilia (median 0.8, IQR 0–2).

3.3 | Labor market participation

The analysis population consisted of 794 individuals aged 15–75 years. Information on labor market status was missing for 24
Table 1: Characteristics of persons with hemophilia aged 5–75 years

| Characteristic, N (%) or Median (IQR) | Total (n = 906) | Severe (n = 339) | Moderate (n = 133) | Mild (n = 434) |
|--------------------------------------|----------------|----------------|----------------|--------------|
| Age                                  |                |                |                |              |
| 43.0 (21–59)                         | 36 (20–54)     | 40 (25–57.5)   | 48 (27–61)     |
| Type of hemophilia                   |                |                |                |              |
| Hemophilia A                         | 783 (86.4)     | 294 (86.7)     | 113 (85.0)     | 376 (87.2)   |
| Hemophilia B                         | 113 (12.5)     | 45 (13.3)      | 19 (14.3)      | 49 (11.4)    |
| Missing                              | 10 (1.1)       | -              | 1 (0.8)        | 9 (2.5)      |
| Treatment modality                   |                |                |                |              |
| Prophylaxis                          | 327 (36.0)     | 303 (89.4)     | 21 (15.8)      | 2 (0.5)      |
| No prophylaxis                       | 553 (61.0)     | 28 (8.3)       | 111 (83.5)     | 414 (95.4)   |
| Missing                              | 27 (3.0)       | 8 (2.4)        | 1 (0.8)        | 18 (4.2)     |
| Hepatitis C infectiona               |                |                |                |              |
| Never                                | 557 (61.5)     | 166 (49.0)     | 81 (60.9)      | 310 (71.4)   |
| Past                                 | 226 (24.9)     | 142 (41.9)     | 38 (28.6)      | 46 (10.6)    |
| Current                              | 7 (0.8)        | 5 (1.5)        | 0 (0)          | 2 (0.5)      |
| Missing                              | 116 (12.8)     | 26 (7.7)       | 14 (10.5)      | 76 (17.5)    |
| HIV positive                         |                |                |                |              |
| No                                   | 853 (94.2)     | 314 (92.6)     | 129 (97.0)     | 410 (94.5)   |
| Yes                                  | 21 (2.3)       | 21 (6.2)       | 0 (0)          | 0 (0)        |
| Missing                              | 32 (3.5)       | 4 (1.2)        | 4 (3.0)        | 24 (5.5)     |
| Inhibitor statusb                    |                |                |                |              |
| Never                                | 732 (80.8)     | 269 (79.4)     | 113 (85.0)     | 350 (80.6)   |
| Past                                 | 85 (9.4)       | 51 (15.0)      | 14 (10.5)      | 20 (4.6)     |
| Current                              | 14 (1.5)       | 4 (1.2)        | 2 (1.5)        | 8 (1.8)      |
| Missing                              | 73 (8.1)       | 13 (3.8)       | 4 (3.0)        | 56 (12.9)    |
| Joint impairmentc                    |                |                |                |              |
| No                                   | 478 (52.8)     | 102 (30.1)     | 67 (50.4)      | 309 (71.2)   |
| Yes                                  | 327 (36.1)     | 205 (60.5)     | 54 (40.6)      | 68 (15.7)    |
| Missing                              | 101 (11.1)     | 32 (9.4)       | 12 (9.0)       | 57 (13.1)    |

Note: Information on ethnicity was not collected because this is not allowed under Dutch law. Abbreviation: IQR, interquartile range.

aTwo individuals with severe hemophilia had a past or current hepatitis C virus infection, but current status could not be established.

bTwo individuals with severe hemophilia had a past or current inhibitor, but current status could not be established.

cJoint impairment is self-reported joint impairment in any joint (yes/no).
Occupational disability was reported by 8.4% (CI 6.5–10.4) of the population aged 15–75 years, higher than among the general male population (4.8%). This was mainly attributable to those with severe hemophilia, in which 14.7% (CI 10.5–18.9) reported an occupational disability (Table 3). Of 12 individuals with a current inhibitor, two had an occupational disability (17%). The majority

### TABLE 2
Educational outcomes for persons with hemophilia and the general male population

| Participation in education, % (95% CI)a | Educational attainment (% with ISCED ≥3 (95% CI)b | Absenteeism from schoolc |
|----------------------------------------|-----------------------------------------------|--------------------------|
| General male population               |                                               |                          |
| 15–19 years                            | 92                                            | 72.8                     | 37.8 n.a.          |
| 20–24 years                            | 53                                            | 76.2 (73.1–79.3)         | 69.5 (63.6–75.3) 1.0 (0–3.3) |
| HiN-6                                  | 96 (90–100)d                                 | 68.1 (57–79)e            | 76.7 (73.6–83.7) 80 (70–90) 2.0 (0.9–4.8) |
| Severe                                 | –                                             | 72.2 (64.0–80.4)         | 77 (22–140) 1.0 (0.2–3) |
| Moderate                               | –                                             | 75.8 (71.3–80.2)         | 54 (38–70) 0.8 (0–2) |
| Mild                                   | –                                             |                          |                          |

Note: Outcomes that are different from the general population are indicated in bold.

Abbreviations: CI, confidence interval; ISCED, International Standard Classification of Education; n.a., not available.

a263 individuals were enrolled in formal education (i.e., ISCED level 1 and higher); 151 of them were between 5 and 18 years old and in compulsory education. One-third (33.8%) of individuals enrolled in education also had full-time or part-time work or was self-employed, and another 3.8% was actively looking for work. General population data are from the Organization for Economic Co-operation and Development (OECD) for males and females combined.32

bHighest completed education level of the hemophilia population and general male population aged 15–75 years. Educational attainment was missing for 63 individuals (8%) with hemophilia and for 1.6% of individuals in the general population. General population data are from Statistics Netherlands.33

cBecause of hemophilia for all individuals aged 15–75 years and enrolled in formal education of any type or level, or absenteeism from school for any illness for Dutch boys in grades 8 and 10 without hemophilia.34

dEducation status was unknown for 2 of 46 individuals. Participation in education was not stratified by severity because of low numbers (n = 18 for mild hemophilia, n = 4 for moderate hemophilia, and n = 24 for severe hemophilia).

eEducation status was unknown for 1 of 72 individuals. Participation in education was not stratified by severity because of low numbers (n = 28 for mild hemophilia, n = 12 for moderate hemophilia, and n = 32 for severe hemophilia).

**FIGURE 1** Distribution of the hemophilia population aged 15–75 years in the labor force and the nonlabor force. The labor force consists of individuals with paid employment >1 hour/week and individuals who are legally unemployed. Persons in the nonlabor force are not able to work or available for work because they are enrolled in (full-time) education, retired, have an occupational disability, or have unpaid employment. *No data were available for the work availability of persons with a part-time job.
Of 273 participants aged 15–75 years with severe hemophilia, 12 (4.7%) reported that hemophilia had affected their choice of education or career to some or to a large extent. This proportion was 17% for moderate hemophilia and 7% for mild hemophilia (Table S3). Among participants born in 1993 or later, 16.5% reported that hemophilia had affected this decision. For participants born between 1971 and 1992, this was 28.6% and for the group born in 1970 or earlier this was 36.1%. Frequently mentioned impacts in the open-ended question were choosing jobs that required little physical activity or that had a low injury risk.

### Limitations labor market

| General male population | HiN-6 | Severe | Moderate | Mild |
|-------------------------|-------|--------|----------|------|
| Employment-to-population ratio | 73.2  | 68.2 (64.9–71.5) | 64.3 (58.6–70.0) | 70.2 (65.6–74.8) |
| Unemployment | 3.4 | 5.4 (3.5–7.3) | 6.9 (4.3–10.5) | 4.3 (1.9–6.7) |
| % working full-time | 72  | 71.4 (67.6–75.3) | 66.9 (59.9–73.8) | 73.3 (68.0–78.6) |
| Occupational disability (%) | 8.4 (6.5–10.4) | 14.7 (10.5–18.9) | 4.2 (0.6–7.8) | 5.3 (3.0–7.5) |
| % with work absenteeism (any reason) | 37.7 (31.4–43.9) | 42.6 (30.9–54.4) | 34.4 (17.9–50.8) | 35.9 (27.7–44.1) |
| % with work absenteeism (hemophilia) | 19.7 (14.5–24.8) | 25.0 (14.7–35.3) | 21.9 (7.6–36.2) | 16.3 (9.9–22.6) |
| Median days (IQR) | n.a. | 0 (0–5) | 0 (0–5) | 0 (0–4) |

Note: Outcomes that are different from the general population are indicated in bold.

Abbreviations: HiN, Hemophilia in the Netherlands; IQR, interquartile range; n.a., not available.

### Table 3

| Labor market indicators | Limitations labor market |
|-------------------------|--------------------------|
| Employment-to-population ratio | Occupational disability (%) |
| Unemployment | % with work absenteeism (any reason) | % with work absenteeism (hemophilia) | Median days (IQR) |
| General male population | HiN-6 | Severe | Moderate | Mild |
|-------------------------|-------|--------|----------|------|
| 73.2 | 68.2 (64.9–71.5) | 64.3 (58.6–70.0) | 70.2 (65.6–74.8) | 71.4 (67.6–75.3) |
| 3.4 | 5.4 (3.5–7.3) | 6.9 (4.3–10.5) | 4.3 (1.9–6.7) | 72 |
| 72  | 71.4 (67.6–75.3) | 66.9 (59.9–73.8) | 73.3 (68.0–78.6) | 8.4 (6.5–10.4) |
| 8.4 (6.5–10.4) | 14.7 (10.5–18.9) | 4.2 (0.6–7.8) | 5.3 (3.0–7.5) | 37.7 (31.4–43.9) |
| 19.7 (14.5–24.8) | 25.0 (14.7–35.3) | 21.9 (7.6–36.2) | 16.3 (9.9–22.6) | 0 (0–5) |

### Table 3.1

Comparison of labor market participation for persons with hemophilia and the general male population aged 15–75 years

| Labor market indicators | Limitations labor market |
|-------------------------|--------------------------|
| Employment-to-population ratio | Occupational disability (%) |
| Unemployment | % with work absenteeism (any reason) | % with work absenteeism (hemophilia) | Median days (IQR) |
| General male population | HiN-6 | Severe | Moderate | Mild |
|-------------------------|-------|--------|----------|------|
| 73.2 | 68.2 (64.9–71.5) | 64.3 (58.6–70.0) | 70.2 (65.6–74.8) | 71.4 (67.6–75.3) |
| 3.4 | 5.4 (3.5–7.3) | 6.9 (4.3–10.5) | 4.3 (1.9–6.7) | 72 |
| 72  | 71.4 (67.6–75.3) | 66.9 (59.9–73.8) | 73.3 (68.0–78.6) | 8.4 (6.5–10.4) |
| 8.4 (6.5–10.4) | 14.7 (10.5–18.9) | 4.2 (0.6–7.8) | 5.3 (3.0–7.5) | 37.7 (31.4–43.9) |
| 19.7 (14.5–24.8) | 25.0 (14.7–35.3) | 21.9 (7.6–36.2) | 16.3 (9.9–22.6) | 0 (0–5) |

Note: Outcomes that are different from the general population are indicated in bold.

Abbreviations: HiN, Hemophilia in the Netherlands; IQR, interquartile range; n.a., not available.

### Table 3.2

Comparison of labor market participation for persons with hemophilia and the general male population aged 15–75 years

| Labor market indicators | Limitations labor market |
|-------------------------|--------------------------|
| Employment-to-population ratio | Occupational disability (%) |
| Unemployment | % with work absenteeism (any reason) | % with work absenteeism (hemophilia) | Median days (IQR) |
| General male population | HiN-6 | Severe | Moderate | Mild |
|-------------------------|-------|--------|----------|------|
| 73.2 | 68.2 (64.9–71.5) | 64.3 (58.6–70.0) | 70.2 (65.6–74.8) | 71.4 (67.6–75.3) |
| 3.4 | 5.4 (3.5–7.3) | 6.9 (4.3–10.5) | 4.3 (1.9–6.7) | 72 |
| 72  | 71.4 (67.6–75.3) | 66.9 (59.9–73.8) | 73.3 (68.0–78.6) | 8.4 (6.5–10.4) |
| 8.4 (6.5–10.4) | 14.7 (10.5–18.9) | 4.2 (0.6–7.8) | 5.3 (3.0–7.5) | 37.7 (31.4–43.9) |
| 19.7 (14.5–24.8) | 25.0 (14.7–35.3) | 21.9 (7.6–36.2) | 16.3 (9.9–22.6) | 0 (0–5) |

Note: Outcomes that are different from the general population are indicated in bold.

Abbreviations: HiN, Hemophilia in the Netherlands; IQR, interquartile range; n.a., not available.
the negative association was more pronounced among those with severe hemophilia (Figure 4).

4 | DISCUSSION

This study assessed socioeconomic participation in Dutch persons with hemophilia. To our knowledge, this is the first comprehensive report of nationwide participation in education, labor market participation, and social participation of persons with hemophilia using internationally recognized socioeconomic standards.

Participation in education and educational attainment of Dutch persons with hemophilia were similar to or higher than among the general population. Absenteeism from school was increased. The most important labor market indicators (i.e., the employment-to-population ratio, unemployment, and occupational disability) were worse than in the general population, especially for individuals with severe hemophilia. Absenteeism from work and the ability to participate in social roles and activities were similar to or better than in the general population. However, the latter was worse for the oldest age group with severe hemophilia.

Most of our results corroborate those of previous reports. However, in contrast with other studies, occupational disability in HiN-6 was lower than reported in other studies, and fewer participants perceived a negative impact of hemophilia on their career or education. These differences may be explained by differences in population and study settings. For example, lower and upper-middle income countries may have higher disability rates than high-income countries such as the Netherlands because of sub-optimal availability of treatment products. On the other hand, unemployment was higher in HiN-6 than in other studies and the general population. The reason for this is unknown, but unemployment rates are known to vary seasonally and according to economic developments. Finally, school absenteeism was much higher than among Dutch boys, which may in part be due to regular hospital visits. However, data may not be comparable because of differences in age groups and reference year.

Occupational disability was almost twice as common. The employment-to-population ratio was 5 percentage points lower than in the general population, especially for severe hemophilia. This does not necessarily imply worse participation because it depends to a large degree on the size of the nonlabor force. Persons in the nonlabor force are not necessarily inactive because of disease, but they may be enrolled in education or be retired. Our study showed large proportions of students and retirees, resulting in a larger nonlabor force and thus a lower employment-to-population ratio. Still, men with hemophilia have a better employment-to-population ratio than 45- to 75-year-old men with a chronic disease (14%).

Our findings of lower absenteeism from work may be explained by a healthy worker effect: working individuals with hemophilia may be relatively healthy and therefore have low absenteeism.

The PROMIS T-scores for Ability to Participate was lower for individuals born before the introduction of prophylaxis, especially for severe hemophilia. This is consistent with PROMIS short form scores of a recent Spanish study among patients with rheumatoid arthritis, spondyloarthritis, and systemic lupus erythematosus. However, we found higher participation rates than for rheumatic disease patients, who had mean scores of 26.2 (SD 7.79). In our study, scores of younger persons with nonsevere hemophilia were higher than in the general population. We cannot explain this finding. Further research is needed to study the determinants of the ability to participate. The differences in participation outcomes with the general population appear to be of the same order of magnitude as those reported in the HiN-5 survey conducted in 2001. However, historic comparisons should be interpreted with caution because of changes in legislation (e.g., for occupational disability), decreasing trends.
in absenteeism, increasing education level in the general population and other labor market developments. Therefore, rather than comparing indicators over time, it is more meaningful to compare socioeconomic participation outcomes for persons with hemophilia with the general population in the same reference year.

This study has several limitations. First, the response rate was 46%. Despite this, the most important characteristics of responders were similar to those of nonresponders in terms of hemophilia severity and age distribution. 48% of persons in our sample had mild hemophilia compared with 53.5% in the Dutch hemophilia population. We therefore consider our results generalizable to the full Dutch hemophilia population. Some selection based on education level or ethnicity is possible because completing a comprehensive questionnaire is a cognitive task that requires sufficient Dutch language skills; individuals with a lower education level or limited ability to understand Dutch (i.e., immigrants) may therefore have been less likely to respond. This may have resulted in possible underrepresentation of these groups and overestimation of educational attainment. Under Dutch law, we were not allowed to collect information on ethnicity. On the other hand, those with higher education levels may have busier jobs and schedules and less time to complete a questionnaire. This source of selection bias is inherent to questionnaire research and may be similar for the previous HiN survey as well as for the surveys conducted by Statistics Netherlands.

Second, we relied on self-reported clinical data for part of our sample because electronic medical record data were not available for 26.6% of participants. Self-reported clinical data may be less reliable, which may have resulted in some misclassification, for example for disease severity. However, low rates of misclassification were observed among those with complete data. Therefore, misclassification is unlikely to have affected our results.

Third, we were only able to compare outcomes with aggregate-level data from the general male population. This may have led to some confounding by age. To overcome this, we stratified our analyses by age groups when possible. However, within-stratum confounding cannot be ruled out completely.

Fourth, reliability of our estimates for unemployment may be limited because of low numbers, resulting in imprecise estimates. The same applies to the employment-to-population ratio and occupational disability for individuals with a current inhibitor. Comparisons with the general population should therefore be interpreted with caution.

Fifth, women with hemophilia were not included in HiN. Our results may therefore not be applicable to women with hemophilia. Finally, the data on work and school absenteeism are incomplete because of a routing error in the electronic version of the questionnaire that occurred until December 2018. This resulted in fewer participants responding to the questions about absenteeism, making our estimates of absenteeism less reliable. The missing data on absenteeism may be considered missing completely at random because missingness is not dependent on any other variable.

The more favorable outcomes of younger compared with older participants and modest improvements since the previous nationwide study suggest beneficial effects of widespread prophylaxis.

**FIGURE 4** Median T-scores on PROMIS Profile-29 Ability to participate in social roles and activities, by hemophilia severity and age group (≥18 years old). Medians are shown as horizontal bars. Boxes indicate interquartile range and whiskers indicate range of T-scores.
Hemophilia treatment is costly. However, treatment has also brought direct and indirect gains for persons with hemophilia and for society because of near-normal participation. Monitoring such outcomes in a standardized manner will help evaluate the long-term effects of comprehensive hemophilia care, including innovations in treatment. Such novel treatments were not yet available at the time the survey was conducted and their effects on socioeconomic outcomes could not be taken into account in this study.

In conclusion, educational outcomes and social participation were similar to or better than in the general population. Some labor market indicators were worse for severe hemophilia. Further research is needed to establish whether comprehensive care contributed to better participation.

**AUTHOR CONTRIBUTIONS**

E.C. van Balen wrote the analysis plan, conducted the analyses, and wrote the manuscript. J.G. van der Bom and S.C. Gouw provided critical comments on design and analysis of the study and the manuscript. All authors provided written feedback and approved the final manuscript.

**ACKNOWLEDGMENTS**

We would like to thank all participants in the HiN-6 study, as well as all nurses, research coordinators, and clinicians in participating hospitals.

**RELATIONSHIP DISCLOSURE**

E.C. van Balen, S. Hassan, C. Smit, M.H. Driessens, E.A.M. Beckers, H.L. Hoomeijer, E.P. Mauser-Bunschoten, and F.R. Rosendaal have no conflicts of interest to disclose. S.E.M. Schols has received travel grants from Bayer and Takeda, consultancy grants from Takeda and Novo Nordisk, and a research grant from Bayer. M. Coppens has received travel grants from Bayer and Takeda, consultancy grants from Takeda and Novo Nordisk, and a research grant from Bayer. C. Smit has received financial support for research from Bayer, CSL Behring, Daiichi Sankyo, Portola/Alexion, Roche, Sanquin Blood Supply, and UniQure and consultancy or lecturing fees from Bayer, CSL Behring, Medcon International, MEDtalks, NovoNordisk, Pfizer, and Sobi. J. Eikenboom received research support from Bayer, CSL Behring, and has been a teacher on educational activities of Roche. F.W.G. Leebeek received unrestricted research grants from CSL Behring, Takeda, UniQure, and Sobi and is a consultant for UniQure, Novo Nordisk, Biomarin, and Takeda, of which the fees go to the institution. He is also a DSMB member for a study by Roche. L.F.D. van Vulpen received research grants from CSL Behring and Grifols and is a consultant for Sobi and Tremeau. All fees go to the institution. J.G. van der Bom has been a teacher on the educational activities of Bayer and received unrestricted research grants from NovoNordisk. S.C. Gouw has received unrestricted research grants from Sobi.

**REFERENCES**

1. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. *Haemophilia*. 2020;26:1-2. doi:10.1111/hae.14046
2. Hassan S, van Balen EC, Smit C, et al. Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019. *J Thromb Haemost*. 2021;19:2394-2406. doi:10.1111/jth.15424
3. Mauser-Bunschoten EP, Bresters D, van Driemelen AA, et al. Hepatitis C infection and viremia in Dutch hemophilia patients. *J Med Virol*. 1995;45:241-246. doi:10.1002/jmv.1890450302
4. Leebeek FWG, Fischer K. Quality of haemophilia care in the Netherlands: new standards for optimal care. *Blood Transfus*. 2014;12:S501-S504. doi:10.2450/2014.0041-14
5. Nederlandse Vereniging van Hemofielbehandelaars (NVHB). Richtlijn Diagnostiek en Behandeling van Hemofiele 2020. Utrecht, 2021.
6. Colvin BT, Astemark J, Fischer K, et al. European principles of haemophilia care. *Haemophilia*. 2008;14:361-374. doi:10.1111/j.1365-2516.2007.01625.x
7. Hassan S, Monahan RC, Mauser-Bunschoten EP, et al. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018. *J Thromb Haemost*. 2020;19:645-653. doi:10.1111/jth.15182
8. Skinner MW, Chai-Adisaksopha C, Curtis R, et al. The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. *Pilot Feasibility Stud*. 2018;4:58. doi:10.1186/s40814-018-0253-0
9. Van Balen EC, O’Mahony B, Cnossen MH, et al. Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes set. *Res Pract Thromb Haemost*. 2021;5:12488. doi:10.1002/rth.12488
10. Pinto PR, Paredes AC, Pedras S, et al. Sociodemographic, clinical, and psychosocial characteristics of people with hemophilia in Portugal: findings from the first national survey. *TH Open*. 2018;2:e54-e67. doi:10.1055/s-0038-1624568
11. Plug I, Peters M, Mauser-Bunschoten EP, et al. Social participation of patients with hemophilia in the Netherlands. *Blood*. 2008;111:1811-1815. doi:10.1182/blood-2007-07-102202
12. Forsyth AL, Gregory M, Nugent D, et al. Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. *Haemophilia*. 2014;20:44-51. doi:10.1111/hae.12239
13. Holstein K, von Mackensen S, Bokemeyer C, Langer F. The impact of social factors on outcomes in patients with bleeding disorders. *Haemophilia*. 2016;22:46-53. doi:10.1111/hae.12760

**ORCID**

Erna C. van Balen https://orcid.org/0000-0002-3678-6581
Shermarke Hassan https://orcid.org/0000-0002-5045-636X
Mariette H. E. Driessens https://orcid.org/0000-0001-7423-8538
14. Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivities in haemophilia patients with inhibitors. *Haemophilia*. 2009;15:911-917. doi:10.1111/j.1365-2516.2009.02032.x

15. Plug I, van der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. *Blood*. 2004;104:3494-3500. doi:10.1182/blood-2004-05-0058

16. Limperg PF, Maurice-Stam H, Haverman L, et al. Professional functioning of young adults with congenital coagulation disorders in the Netherlands. *Haemophilia*. 2019;25:e138-e145. doi:10.1111/hae.13698

17. O’Hara J, Noone D, Jain M, et al. Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A. *Haemophilia*. 2021;27:938-946. doi:10.1111/hae.14302

18. International Labour Office. *Key Indicators of the Labor market*, 9th ed. 2016.

19. National Institute for Public Health and the Environment (RIVM). Absenteeism and occupational disability (Ziekteverzuim en arbeidsongeschiktheid). *Volksgezondheidszorginfo*. Bilthoven 2020.

20. Smit C, Rosendaal FR, Varekamp I, et al. Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85. *BMJ*. 1989;298:235-238. doi:10.1136/bmj.298.6668.235

21. Triemstra AHM, Smit C, Ploeg HM, Briët E, Rosendaal FR. Two decades of haemophilia treatment in the Netherlands, 1972-2002. *Haemophilia*. 1995;1(3):165-171. doi:10.1111/j.1365-2516.1995.tb00061.x

22. Rosendaal FR, Smit C, Varekamp I, et al. Modern haemophilia treatment: medical improvements and quality of life. *J Intern Med*. 1990;228:633-640. doi:10.1111/j.1365-2796.1990.tb00291.x

23. Castor EDC. Castor electronic data capture. 2019.

24. van Balen EC, Haverman L, Hassan S, et al. Validation of PROMIS Profile-29 in adults with hemophilia in the Netherlands. *J Thromb Haemost*. 2021;19:2687-2701. doi:10.1111/jth.15454

25. Cella D, Gershon R, Lai JS, Choi S. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. *Qual Life Res*. 2007;16:133-141. doi:10.1007/s11136-007-9204-6

26. Cella D, Choi SW, Condon DM, et al. PROMIS (R) adult health profiles: efficient short-form measures of seven health domains. *Value Health*. 2019;22:537-544. doi:10.1016/j.jval.2019.02.004

27. UNESCO Institute for Statistics. International Standard Classification of Education: ISCED 2011. Montreal, 2012.

28. Ministerie van Onderwijs Cultuur en Wetenschappen, Dienst Uitvoering Onderwijs, Statistics Netherlands (CBS). Toedeling Nederlandse onderwijsprogramma’s (ISCED). *Onderwijs in Cijfers*. Den Haag 2011.

29. Rijksoverheid. Exemptions from compulsory school attendance (Leerplicht en kwalficatieplicht). Den Haag 2021.

30. Statistics Netherlands (CBS). Definitions. Den Haag 2021.

31. Cella D, Gershon R, Bass M, Rothrock N. *HealthMeasures Scoring Service*. Northwestern University; 2007.

32. OECD. *Education at a Glance 2020: OECD Indicators*. 2020.

33. Statistics Netherlands (CBS). Bevolking; onderwijsniveau; geslacht, leeftijd en migratieachtergrond [Educational attainment]. Den Haag 2019.

34. National Institute for Public Health and the Environment (RIVM). Gezondheidsmonitor Jeugd. *Volksgezondheidszorginfo*. Bilthoven: RIVM, 2015.

35. Statistics Netherlands (CBS). Arbeidssdeelname; kerncijfers [labor participation; core figures]. Den Haag 2018.

36. Statistics Netherlands (CBS). Ziekteverzuim volgens werknemers; geslacht en leeftijd [Absenteeism from work] *Nationale Enquête Arbeidsomstandigheden [National Survey of Employment circumstances]*. Den Haag 2018.

37. Katz P, Pedro S, Alemao E, et al. Estimates of responsiveness, minimally important differences, and patient acceptable symptom state in five patient-reported outcomes measurement information system short forms in systemic lupus erythematosus. *ACR Open Rheumatol*. 2020;2:53-60. doi:10.1002/acr2.11100

38. Dillingh R, Ebbrejt J, Holmer K, Jongen M, Scheer B, Zweerink J. Arbeidsparticipatie [labor participation]. CPB Notitie. Den Haag CPB Netherlands Bureau for Economic Policy Analysis, 2018.

39. De Putter I, Kappen H, Oldenkamp M, Spreeuwenberg P, Aussen C, Boeije H. Langer doorwerken - voor iedereen? Ontwikkelingen in de arbeidsstatus van 45- tot 75-jarigen met een chronische ziekte of lichamelijke beperking. monitor 2005-2017 [Monitor Development of employment situation among persons aged 45-75 with a chronic illness]. In: Nivel, ed. Utrecht, 2019.

40. Pearce N, Checkoway H, Kriebel D. Bias in occupational epidemiology studies. *Occup Environ Med*. 2007;64:562-568. doi:10.1136/oem.2006.026690

41. Cano-García L, Mena-Vázquez N, Manrique-Arija S, Redondo-Rodriguez R, Romero-Barco CM, Fernández-Nebro A. Ability to participate in social activities of rheumatoid arthritis patients compared with other rheumatic diseases: a cross-sectional observational study. *Diagnostics*. 2021;11:2258.

42. National Institute for Public Health and the Environment (RIVM). Trends in occupational disability (Trends in arbeidsongeschiktheid). *Volksgezondheidszorginfo*. Bilthoven 2020.

43. Jongen E, Koot P, Dillingh R, Ebbrejt J. Dalende arbeidsparticipatie van jonge mannen – een vooronderzoek. Den Haag: CPB Netherlands Bureau for Economic Policy Analysis, 2021.

44. Grobbee DE, Hoes AW. *Clinical Epidemiology: Principles, Methods, and Applications for Clinical Research*. 2014.

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Van Balen E, Hassan S, Smit C, et al. Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study. *Res Pract Thromb Haemost*. 2022;6:e12741. doi:10.1002/rth2.12741